Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUGUST II: Atacicept in Anti-TNFα-naïve RA
NCT00595413Phase 2Completed
- Sponsor
- EMD Serono
- Start
- Sep 2007
- Primary completion
- Oct 2009
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of atacicept in rheumatoid arthritis (RA) (4 arms), sponsored by EMD Serono. Primary endpoint: American College of Rheumatology 20 Response Based on C-reactive Protein at Week 26. Started Sep 2007; status: completed.
02
Drugs
atacicept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00595413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00595413.